REGN

Business Context and Reporting Period

Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for serious medical conditions. The company has no approved products for sale and has not generated profits from commercialization since inception. Its strategy relies on proprietary technology platforms (Velocigene, Trap Technology) and strategic collaborations to advance a pipeline of product candidates for cancer, eye diseases, rheumatoid arthritis, asthma, and obesity.

Key Financial Metrics

Revenue Composition (2003):

• Contract Research & Development: $47.4 million (Driven by new collaborations with Novartis and Aventis).
• Contract Manufacturing: $10.1 million (Primarily from Merck).

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased 161% to $57.5 million, primarily due to the recognition of $21.4 million from the Novartis collaboration and $14.3 million from the Aventis collaboration. These agreements included significant non-refundable up-front payments ($27.0 million and $80.0 million, respectively) and stock purchases.
• Improved Net Loss: Net loss decreased by $16.9 million compared to 2002, despite a $11.0 million increase in R&D expenses. The improvement was driven by the substantial increase in collaboration revenue.
• Collaboration Shifts:
  • Aventis: Entered a major agreement in September 2003 to jointly develop the VEGF Trap. Aventis funded $10.7 million of development costs in 2003.
  • Novartis: Entered an agreement in March 2003 for the IL-1 Trap. However, in February 2004 (post-period), Novartis notified Regeneron of its intention to terminate the joint development of the IL-1 Trap.
• Accounting Change: The company adopted the "Substantive Milestone Method" for revenue recognition of non-refundable collaborator payments, applied retroactively to January 1, 2003.

Guidance, Outlook, and Risks

Outlook & Guidance:

• 2004 Expenses: R&D expenses are expected to increase 15-30% in 2004. Average headcount is projected to rise to 730-750 employees.
• Liquidity: Management believes existing capital resources will meet operating needs through at least the end of 2005.
• Clinical Plans:
  • VEGF Trap: Plans to complete Phase I cancer trials and commence Phase II cancer trials and Phase I eye disease trials in 2004.
  • IL-1 Trap: Plans to initiate a Phase IIb study in rheumatoid arthritis in the second half of 2004, despite Novartis's withdrawal.
  • AXOKINE: No new Phase III trials planned for 2004; focus is on completing safety extension trials and evaluating commercial potential.

Key Risks & Contingencies:

• Novartis Termination: Novartis's decision to exit the IL-1 Trap collaboration creates uncertainty regarding funding and commercialization capabilities for this candidate.
• Product Liability Litigation: Securities class action lawsuits were filed in May 2003 alleging misstatements regarding AXOKINE safety and efficacy. No reserve has been established as the company believes the claims are without merit.
• Debt Obligations: The company has $200 million in convertible senior subordinated notes maturing in 2008 with a 5.5% interest rate. Failure to generate cash flow could impair the ability to service this debt.
• Development Uncertainty: Clinical trials are expensive and uncertain. Previous trials for AXOKINE showed modest weight loss, and the IL-1 Trap Phase II trial failed to achieve statistical significance on its primary endpoint.

Investor Verification Checklist

• Novartis Termination Impact: Verify the specific financial and operational consequences of Novartis's February 2004 notice to terminate the IL-1 Trap collaboration, including the status of the $13.8 million loan and future funding obligations.
• Revenue Recognition Policy: Review the details of the "Substantive Milestone Method" adoption and its impact on the timing of revenue recognition for the Aventis and Novartis up-front payments.
• AXOKINE Commercial Viability: Assess the commercial potential of AXOKINE given the modest efficacy results in Phase III and the competitive landscape of oral obesity treatments versus injectables.
• Debt Service Capacity: Confirm the company's ability to meet semi-annual interest payments on the $200 million convertible notes without additional equity financing.
• Legal Proceedings: Monitor the status of the securities class action lawsuit regarding AXOKINE disclosures.